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1. Introduction 
Since Wilhelm Röntgen reported his novel discovery of the X- Ray in 1895(Röntgen, 1898 as 
cited in Weinmann etal., 2005), the Diagnostic imaging has been an integral part of 
medicine. He was decorated by the second class of Prussian crown medal and he was also 
awarded the first physic Nobel Prize at 1901. Levy- Dorn was another pioneer in radiology 
who understood the potential importance of X-ray in medicine and opened a daily private 
office for medical examination with X-ray in 1896 just one year after innovation of X-ray by 
Röntgen. He pointed to the danger of this method to the living organism very early 
(Hierholzer K & Hierholzer J 1997; Nitze, 1895; as cited in Hierholzer K & Hierholzer J, 2002)  
Since X-rays are not sufficiently absorbed by soft tissue, contrast media (CM) is used to 
highlight organs or pathologies. Osborne etal reported that inorganic Iodine enhanced the 
urinary tracts X-ray images (Osborn etal., 1923). But the most important contributor to the 
field of urological imaging came from the field of agriculture when A Binz and C Räth, two 
scientists from the Berlin agricultural college synthesized a new organic iodinated molecule 
"Selectan"(Binz & Räth 1928 as cited in Hierholzer K & Hierholzer J, 2002), and a research 
fellow used this agent in clinical investigations. (Swick 1929a, 1929b as cited in Hierholzer K 
& Hierholzer J, 2002; Weinmann etal., 2005). 
 In 1928 an urologist, Forssmann, used one of these agents in his own coronary arteries 
(Hricak & Barbarive 1984).This was an unexpected methodological contribution of 
urological research to cardiology.   
From 1929 on, serial production of Uroselectan was established. This agent was a big step 
forward in safety, because ionic iodide (Sodium Iodide and Lithium Iodide) cannot be used 
in a clinical setting. In the early 1950s, a new generation of iodinated agents was launched, 
which were derivatives of triiodinated benzoic acid, e.g. diatrizoate (Urografin etc.). These 
agents became standard in diagnostic imaging for the next 30 years and are still widely used 
in many countries. Almen suggested that non-ionic molecules could reduce osmolality 
(Almen, 1969, as cited in Weinmann etal., 2005), an idea that was the basis of safer 
compounds that entered routine clinical use in the 1980s. Water-soluble, non-ionic iodinated 
contrast agents are now the workhorses in contrast based imagings. More than 90% of 
contrasts media are used in western countries are non-ionic CM. 
There are two main complications of contrast media. The aim of this chapter is to discuss 
these two major side effects of CM. the most important of these two complication is contrast 
induced nephropathy (CIN) which will be described in details and the other is anaphylaxis 
reactions to the CM which will be mentioned briefly at the end of the chapter. 
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2. Contrast induced nephropathy 
According to the report of American Heart Association statistics committee and stroke 
statistics subcommittee updated at 2007, from 1979 to 2004 the number of cardiac 
catheterization has been increased 334%. Meanwhile from 1987 to 2004 the number of 
percutaneous coronary intervention (PCI) has also increased 326%.IN 2004 more than 
1,297.000 cardiac catheterization and in 2006 at least 1,313,000 PCI were performed in U.S 
(American Heart Association statistics committee and stroke subcommittee, 2007). In 2003, 
about 80 million doses of CM were used worldwide (Persson, 2005). Now in U.S more tha 10 
millions radiological examinations with CM are performed annually which 4 millions of 
these procedures are cardiac catheterizations. In western countries 6000 diagnostic cardiac 
catheterization and 2000 therapeutical procedure are done per 1million habitants (Costa, 
2004; Ultramari etal., 2006). On the other hand the physicians are dealing with a significant 
increase in the prevalence and incidence of cardiovascular diseases, chronic kidney diseases 
and diabetes which are considered as risk factors of CIN development. All these patients are 
in increased need to such a diagnostic and the therapeutical maneuver.  
CIN is a very interesting Issue for researchers. It is a type of acute kidney injury (AKI) which 
in contrast to all other causes of AKI, the exact time of injurious insult is known. 
Accordingly, it may help the investigators to find a more preciously diagnostic tool beside 
to develop more effective prophylactic and therapeutical interventions. 
CIN is a matter of health conflicts. It is an important causes of increased resource utilization, 
prolonged hospital stay, increased in hospital and long term mortality and provoke the 
progression of CKD (Bartholomew etal., 2004; Goldenberg etal., 2009; Gruberg etal., 2000; 
James etal., 2010; McCullough etal., 1997; Solomon etal., 2009; Subramanian etal., 2007). 
2.1 Physicochemical properties and classification of Contrast Media (table1) 
CM is derivatives of tri-Iodinated benzene and is classified according to their Ionization, 
osmolality and structural properties. The ionized media are dissociated in water, while the 
nonionic agents are not dissociated although they are soluble in water. The ratio of iodine to 
dissolved particles, describes an important relationship between opacification and 
osmotoxicity of a contrast agent, higher this ratio, more desirable. In high osmolal CM this 
ratio is 1.5, which in low-osmolal and iso-osmolal CM this ratio is 3 and 6 respectively. With 
lowering the osmolality, the viscosity will increase. Viscosity has some deleterious effect on 
renal blood flow and urinary flow in tubules. Contrast agents are completely filtered. With 
reabsorption of water in tubules the concentration of CM reaches 50-100 times of plasma 
concentration. 
The first generation CM was Ionic. They had 3 atoms of Iodine, one atom of sodium and 2 
active osmotic particles in each molecule,therefore their osmolality was very high (1200-1800 
mosm/kgH2o), so they called hyper-osmolal contrast media (HOCM). From late 80s, the 
next generation of these agents has been marketed. They are non-Ionic. They have only one 
somatically active particle. They have been known as Low-osmolal Contrast Media (LOCM) 
because their osmolality is lower than first generation but yet significantly higher than 
plasma osmolality (600—900 mosm/kgH2o). The third generation of CM is Iso-osmolal 
Contrast Media (IOCM) (≈300 mosm/kgH2o). They are non-ionic dimers. They have two 
benzene rings rather than one ring of previous generations. This structure allows 6 Iodine 
atoms to attach to the one cosmetically active particle. 
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Type Name osmolality ionicity mono/dimer
amount of 
iodine 
iodine 
ratio
viscosity 
  (mosm/kg water)   mg/mL  mPa.sec at 370c 
   
HOCM Iothalamat 1695 Ionic monomer 400 3:2 2.8 
LOCM Iomeprol 720 nonionic monomer 350 3:1 4.8 
LOCM Iopentol 683 nonionic monomer 310 3:1 6.5 
LOCM Iopromide 586 nonionic monomer 350 3:1 4.7 
LOCM Iopamidol 653 nonionic monomer 300 3:1 4.6 
LOCM Ioversol 719 nonionic monomer 320 3:1 6 
LOCM Iohexol 667 nonionic monomer 300 3:1 5.7 
LOCM Ioxaglate 584 ionic dimer 320 3:2 7.8 
IOCM Iodixanol 290 nonionic dimer 320 6:1 11.4 
Table 1. Types of contrast media and their physicochemical properties 
2.2 Definition & diagnosis 
Definition of CIN is a matter of controversy and there is no a unique accepted definition. 
CIN is a rapid decline in renal function after CM administration while there is obviously no 
other causes of acute kidney injury (AKI). 
Serum creatinine is the standard marker for detecting CIN. Small changes in serum 
creatinine after CM exposure are seen but it is not considered clinically relevant. 
In last two decade, different criteria of renal function deterioration were defined in clinical 
trials. But the two most popular are: 1- A 25% relative increase of serum creatinine from 
baseline and 2- An absolute increase of 0.5 mg/dl of serum creatinine from the base. It will 
happen within 2 days to one week after contrast exposure. None of these two criteria are 
accurate. The most common method for the assessment of kidney function consists of using 
the Glomerular Filtration Rate (GFR) which usually measured by creatinine clearance. But 
serum creatinine is not a real-time marker of change in kidney function. It is neither a 
specific nor a sensitive marker of GFR evaluation.  In the case of rapid changes in kidney 
function serum creatinine has a 48-72 hours delay related to GFR changes. It cannot show 
the small changes of GFR too, and other factors rather than GFR may affect the blood level 
of serum creatinine. Even in patients with stable serum creatinine the GFR may significantly 
be declined. So many investigators are trying to redefine the cutoff point level of serum 
creatinine increment. For instance the recent definition of AKI, considers a 0.3 mg/dl 
increase of serum creatinine as an evidence of AKI development rather than a 0.5 mg/dl 
increase (Shah & Mehta, 2006). Weisbord etal showed that only a 0.25-0.3 mg/dl increase in 
serum creatinine after coronary angiography was accompanied with significant increase of 
mortality within 30 days of procedure (Weisbord etal., 2006). In another study only a 5% 
increases of serum creatinine within 12 hours after the contrast exposure had 75% sensitivity 
and 72% specificity for detecting CIN. It also had a strong correlation with the development 
of renal failure during next 30 days (Ribichini etal., 2010). 
Recently more sensitive markers of GFR have been developed and validated. The most 
promising markers are Cystatin-C and Neutrophilic Gelatinase Associated Lipocaline 
(NGAL). Cystatin-C may be more accurate than serum creatinine in predicting renal 
function. In patients with GFR lower than 60ml/min, Cystatin-C may be a better marker of 
both early detection of CIN and prediction of major side effects like death and chronic 
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dialysis. But it is not known whether the increased level of Cystatin-C is due to the 
decreased GFR or it is released from atherosclerotic plaques during angiography .If 
Cystatin-C increases by more than 10% within 24 hours, then it is a good marker of CIN 
occurrence and further events. But an increase of less than 10% from baseline will rule out 
the diagnosis of CIN and the patient can be discharged without any caution (Briguori etal., 
2010).There is no study to evaluate the validity of Cystatin-C in earlier time. Cystatin-C has 
to be better validated in different situations.  
NGAL is also an early diagnostic biomarker of acute kidney injury, but studies for 
validating this biomarker in CIN are limited. It’s specificity and sensitivity in diagnosis of 
CIN in children has been identified (Hirsch etal., 2007). 
 The most accurate method for measuring GFR is radionuclide techniques which are 
expensive and labor-intensive. The Cockcroft-Gault or MDRD equations are useful for the 
calculation of GFR in clinic. 
The problem with Studies, regarding CIN is that nearly in all these studies contrast 
nephropathy is defined by serum creatinine increment which is a soft outcomes value. If 
hard outcomes like the need for dialysis, readmission, other clinical complications and death 
are considered, it may cause better understanding the nature of AKI including CIN and 
therefore its better management.  It may also be more useful if RIFLE classification is taken 
into account rather than Acute Kidney Injury Network criteria for better definition of CIN. 
Further studies should be done to validate this classification for CIN diagnosis. 
The differential diagnosis of CIN is cholesterol atheroemboli, volume depletion and 
interstitial nephritis. 
2.3 Incidence 
CIN is the third cause of AKI in hospitalized patients. The cumulative incidence of CIN is 
10% of all AKI (Tepel etal., 2006). The incidence of CIN in patients without any risk factor is 
0.6-2.3%, but in high risk patients it will be raised up to 90% (McCullough etal., 2006A ; 
Toprak & Cirit 2002). In two studies in 1979 and 2002, CIN was the third cause of in-hospital 
AKI (Nash etal., 2002). These studies showed no change in the incidence of CIN in this 
period (12% in 1979 and 11% in 2002).  
 Three factors increase the incidence of CIN in future: 1) increase in burden of CKD, 2) 
Increase in incidence of diabetes, and 3) increase in diagnostic and therapeutically measures 
requiring CM. 
The incidence of CIN is dependent on the renal function. With serum creatinine more than 
1.3mg/dl and more than 1 mg/dl in men and women respectively the risk of CIN will 
significantly increase (Lamiere etal., 2006). It has been shown that by increasing serum 
creatinine from 1.2 to 2.9mg/dl the risk of CIN increases from 4% to 20% (Barrett etal., 
1992;). The incidence of CIN in patients with serum creatinine of 3 mg/dl with or without 
diabetes is more than 30%.In another study the risk of CIN in patients with serum creatinine 
equal to1.5mg/dl was 8%, but with serum creatinine of 6.8mg/dl the risk of CIN has been 
increased to 92% (McCullough etal.,1997). In patients with normal renal function, even in 
the presence of diabetes or other risk factors the incidence of CIN is less than 2% ( Lamiere 
etal., 2006). The incidence of CIN in diabetic patients with normal serum creatinine is 3.7% 
(Rihal etal., 2002).In patient with severe renal failure and diabetes the need to dialysis will 
be increase to 12% if CIN develops after CM exposure (Manske etal.,1990). 
With regards to coronary angiography the incidence of CIN after this procedure has been 
reported to be 3-14%. Only 2% of patients without diabetes and with serum creatinine of 1.1 
mg/dl will develop CIN after coronary angiography (McCullough etal.,1997; Rihal etal., 2002).  
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2.4 Natural course 
The natural history of CIN includes an increase of serum creatinine mostly after 24 hours of 
CM exposure, which picks in 3-7 days and return to normal within 2 weeks. Most patients 
are non-oliguric but the urine output is usually declined (Rudnick etal., 1995).   
CIN is generally and potentially a reversible acute renal failure, but it should not be 
considered as a benign disorder, because in 30% of patients, renal function would not be 
fully recovered (Maydoon etal., 2001). The patients with CIN rarely need dialysis. According 
to a study among 0.8% of patients who needed dialysis after PCI, 13% remained on dialysis 
for lifetime (McCullough etal., 1997). Another study reported that 13-50% of CIN patients 
who had needed renal replacement therapy, they may remain on dialysis for the rest of life 
(Toprak, 2007). If even CIN recovered completely, it will cause more morbidities including 
bleeding, infection, prolonged hospital stay, increased resource utilization, increase in the 
risk of CKD and increased in-hospital and long term mortality rate (Gruberg etal., 2000; 
Perazella, 2009; Rihal etal., 2002). CIN also causes increase in cardiovascular morbidities. 
The rate of both in-hospital and long term mortality will also significantly be increased due 
to CIN (Gruberg etal., 2000; Liss etal., 2006; Marenzi etal., 2004; McCullough etal., 1997; 
Rihal etal., 2002, Weisbord etal., 2006). The overall mortality rate of patients with CIN is 1.1-
34%, but it is not obvious that CIN perse is the cause of mortality or CIN is more prevalent 
in patients who are sicker and their co-morbidities are more than control patients 
(McCullough etal., 1997 Rudnick & Feldman, 2008). 
 The in-hospital mortality rate of CIN is estimated to be 22-25%. Meanwhile the rate of death 
within 5 years is significantly higher in this group of patients in comparison with control 
group (McCullough etal., 1997; Rihal etal., 2002). Odds of in-hospital death are related to 
rate of serum creatinine increment (Weisbord etal., 2006). CIN is a cause of CKD in the 
coming months (Liss etal., 2006). Although it is not known that whether the direct 
nephrotoxic effect of contrast agents is the cause of CKD or the background renal disease 
will be unmasked by CIN. 
2.5 Risk factors 
The risk factors of CIN are shown in table 2. Previous chronic kidney disease (CKD) is the 
leading and the single most important risk factor of CIN (McCullough etal., 2006B; Rihal 
etal., 2002; Rudnick etal., 1995). The most important cause of delaying or cancelling 
angiography is renal failure. In a recent cohort, the Glomerular Filtration Rate (GFR) of 60 
ml/min considered as a cutoff point (Bartholomew etal., 2004; Mehran etal., 2004). Diabetes 
is the second most important risk factor of CIN (McCullough etal., 1997,2006; Rudnick etal., 
2006; Weisberg etal., 1994). It remains unclear whether diabetes is a risk factor of CIN perse 
or it makes the patient prone to this complication because nearly all diabetic patient have 
overt or covert renal disease (Manske etal., 1990). So the diabetic patients with CKD are the 
highest risk group (McCullough etal., 2006aTepel etal., 2006; Toprak & Cirit, 2006).  
Class IV heart failure is another risk factor of CIN (McCullough etal., 2006B). Many of these 
patients also have several other risk factors like renal disease (atherosclerotic renal disease) 
or decreased effective circulating volume and low GFR. Acute myocardial infarction (AMI) 
is another independent risk factor of CIN if the CM is given within 24hours after the AMI 
(Rihal etal., 2002; Marenzi etal., 2006a). S-T elevation myocardial infarction (STEMI) also 
increases the risk of CIN in the time of PCI. The mortality rate of these patients is high too. 
There is a positive correlation between the mortality rate of these patients and the volume of 
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contrast that is being used for coronary angiography (Marenzi etal., 2006b). Old age 
(Iokavou etal., 2003), hypovolemia (McCullough etal., 2006B) and hypotension are other risk 
factors of CIN. Hypovolemia is among few risk factors which are preventable and should be 
corrected promptly before starting the procedure. The medications that cause extra-cellular 
contraction like diuretics or cause vascular tonicity changes like non-steroidal anti-
inflammatory drugs (NSAIDS) may be involved in development of CIN or at least may 
increase the severity of the disease. The use of angiotensin converting enzyme inhibitors 
(ACIs) or angiotensin receptor blockers (ARBs), while the blood pressure is in normal range 
are not considered contraindicated and could be continued. 
 
Patient related factors                                                Procedure related factors 
CKD                                                                              hyper-osmolal CM 
Diabetes mellitus                                                           high volume of CM 
Age                                                                                repeated exposure to CM within 24 hours 
Hypovolemia                                                                 intra-arterial injection of CM 
Hypotension 
Low ejection fraction 
Class IV CHF 
Concomitant use of other nephrotoxics 
Hypoalbumenimeia (<3.5g/dL) 
Renal transplantation 
Recent AMI (24 hours before angiography) 
Anemia 
_________________________________________________________________________________ 
Table 2. Risk factors for CIN 
Low hematocrite is associated with increased risk of CIN (Nikolsky etal., 2005), but there is 
no study to show that correction of anemia will decrease the incidence of CIN. 
There are few retrospective studies showing high incidence of CIN in renal transplanted 
patients (up to 21%), but these patients had other risk factors like diabetes, renal failure, 
concomitant use of nephrotoxic agents and volume depletion (Ahuja etal., 2000). The 
coronary artery bypass graft (CABG) at the day of angiography will also increase the risk of 
CIN (Ranucci etal., 2008). Nowadays in contrast to what is mentioned in the literature 
multiple myeloma is not considered as a risk factor for CIN. 
2.6 Type of CM  
The safety of a contrast agent depends in large part on the amount of CM that must be 
administered. The body’s ability to tolerate any substance depends on the amount given. 
Even isotonic saline is toxic at very large doses. High dosages that disturb the ionic and 
osmotic balance in the body will elicit adverse reactions without exhibiting a direct 
interaction with other molecules (chemotoxicity). This kind of toxicity is based on the 
osmotic activity of the agent or, more precisely, on the osmotic load (mosmol/kg body 
weight). The important properties of a CM that determine its nephrotoxicity are: osmolality, 
volume, and repeated use, route of use, viscosity and Ionicity. 
Here we briefly review the role of each of the properties of a CM in the development of 
CIN. 
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2.7 Osmolality / viscosity (Table2) 
Now the HOCM is completely replaced by LOCM or IOCM. There is no doubt that 
osmolality is a main factor in nephrotoxicity of a CM (Barrett & Carlisle, 1993; Rudnick & 
Goldfarb, 2003). Although in patients with normal renal function this factor is not important 
(Barrett & Carlisle, 1993). But in chronic renal failure patients, particularly in diabetic 
patients, use of HOCM is contraindicated (Solomon, 2005, Solomon & Dumouchel, 
2006).The incidence of CIN with HOCM in patients with risk factors is two times in 
comparison with LOCM (Barrett & Carlisle, 1993). 
All studies showed that nephrotoxicity of low osmolal media is lower than hyperosmolal 
one (Barrett & Carlisle, 1993; Rudnick etal., 1995), but there are many controversies about 
the difference of LOCM and IOCM in terms of CIN (Aspelin etal., 2003; Barrett etal., 2006; 
Carraro etal., 1998; Liss etal., 2006; McCullough etal., 2006C; Rudnick etal.,2006; Solomon 
etal.,2007; Thomsen etal., 2008).The viscosity of IOCM is higher than LOCM and this 
property of IOCM may offset the benefit of lower osmolality of newer developed agents 
(Aspelin etal., 2003; Barrett & Carlisle, 1993; Rudnick & Goldfarb, 2003, Seeliger etal., 2007). 
Systematic reviews were not also able to solve the contradictory results concerning the 
difference between low and iso-osmolal CM (Heinrich etal., 2009, Reed etal., 
2009,McCullough etal., 2006C., Solomon & Dumouchel, 2006). NEPHRIC study showed that 
with IOCM the risk of CIN in high risk diabetic patients is significantly lower than LOCM 
(Aspelin etal., 2003). This study is criticized by few numbers of patients. In a meta-analysis it 
was also shown that IOCM are less nephrotoxic than LOCM (McCullough etal,. 2006C), but 
in another larger meta-analysis there was no significant difference between LOCM and 
ICOM in term of nephrotoxicity (Heinrich etal., 2009). In a retrospective study, LOCM was 
less nephrotoxic than IOCM (Liss etal., 2006). This study showed that the risk of renal failure 
in future is increased by IOCM whether they had CIN or not. 
According to the published studies, the American college of cardiology/American Heart 
association (ACC/AHA) recommended that there is no difference between low and iso-
osmolal agents in CKD patients. The exception is Iohexol and Ioxaglate. The IOCM has 
lower probability of CIN than these two LOCM (Kushner etal., 2009). 
The exact role of Ionicity in development of CIN is not known. The only meta-analysis in 
this regard showed that Ionic IOCM is similar to nonionic LOCM (Barrett & Carlisle, 
1993). 
2.8 Contrast Media volume 
There is a direct relation between dose of CM and CIN development (Manske etal., 1990; 
McCullough etal., 1997; Rudnick et al., 1995). The probability of CIN is increased with 
higher volume of CM. On average, in coronary angiography, PCI and CT scan 130cc, 190cc 
and 100 to150cc CM is used. Although it has been shown that no patient with less than 100cc 
CM has developed CIN (Gruberg etal., 2001; McCullough etal., 1997), but unfortunately 
wide range of the volume of CM defined as cut off value (30-200cc). The relation between 
the dose of CM and CIN is particularly evident in moderate to severe renal failure patients 
(CKD3-5) which they should be received ultra-low dose of CM. Unfortunately, the need for 
CM for interventional purposes is much higher than this safe volume (250-300cc). In the 
study of Rihal etal it has been shown that with each 100cc CM, the risk of CIN will be 
increased 12% (Rihal etal., 2002). In another study the risk of CIN is serious when the 
volume of CM exceeds more than 3.7 fold of creatinine clearance (Laskey etal., 
2007).Repeated use of CM within 72 hours increases the risk of CIN  
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3. Pathogenesis 
The primary mechanism of CIN is Ischemia and direct tubular toxicity of CM to epithelial 
tubular cells.In experimental studies, after contrast infusion there is an early brief 
vasodilatation of renal vasculature, followed by a long term vasoconstriction (Arakawa etal., 
1996; Seeliger etal., 2007). This biphasic response has not been evident in human and mostly 
increase of renal blood flow has been shown (Weisberg etal.,1992). These studies carried out 
the direct measurement of blood flow by hemodilution techniques. Nevertheless, if renal 
blood flow is measured directly by an intra-renal artery guide-wire, no difference of blood 
flow could be detected at the time of ventriculography, while subsequently by further CM 
infusion, the blood flow is decreased by3.7-39.5% from base (Mockel etal., 2008).Although 
these studies showed mild to moderate decrease of renal blood flow after exposure to CM, 
these findings nevertheless cannot describe the longitudinal decrement of GFR in CIN 
patients. 
3.1 Medullary Hypoxemia 
To overcome the discrepancy between renal blood flow rate and GFR decrement, medullary 
Hypoxemia due to regional blood flow changes is in the focus of attention in describing the 
pathophysiology of CIN. According to this hypothesis, the pathogenetic axel of CIN is 
medullary hypoxemia (Agmon etal., 1994; Heyman etal, 2008). 
Physiologically, blood flow in outer medulla is low and this part of nephron works in 
relatively hypoxic state. The cause of this condition is the unique structure of vasa recta 
which is vital for countercurrent solute exchange. Low blood flow of medulla is also 
important to maintain the gradient in distal nephron. Meanwhile the thick ascending Limb 
of Henle as a hard worker of nephron needs a high level of oxygen. Due to this 
contradictory status, this part of nephron is more vulnerable to ischemic injuries. The 
decrease of blood flow in outer medulla is critical. In normal physiological conditions, the 
mechanisms responsible for blood flow and tubular transport are tubule-glomerular 
feedback, autoregulation and glomerulo-tubular balance which operate hand in hand to 
maintain the integrity of nephron and the system to work properly. The vasodilators (nitric 
oxide, prostaglandins, adenosin, dopamin, urodilantin) and vasoconstrictors (local 
endothelin, AngiotensinII, vasopressin) and transport inhibitors (PDF2, Adenosin, 
dopamine) together balance the supply and demand of oxygen in this part of nephron. 
Release of vasoconstrictor mediators or blockade of vasodilator mediators may play a role in 
the pathogenesis of CIN (Heyman etal., 1994). CM makes imbalance of these mediators. 
They cause decrease of oxygen tension both in cortex and medulla. It may be due to 
increased work of active transport in medullary tick ascending limb of Henle in response to 
osmotic diuresis of hyperosmolal agents.  
Proximal tubules reabsorb a scant amount of CM. The osmotic property of CM causes less 
water reabsorption and increased intra-tubular pressure. The distal delivery of salt and 
water will be increased in this state which in turn activates tubule glomerular feedback and 
decreased GFR. 
Increased pressure of intrestitium is also a factor for decreasing GFR. It also causes 
medullary hypoxia. CM may decrease renal blood flow by direct vasoconstriction of renal 
vasculature. This effect may be due to the change of calcium metabolism (Bakris & Burnett, 
1985), or local increase of adenosin (Pflueger etal., 2000) and endothelin (Bagnis etal., 1997). 
By CM infusion, the oxygen tension in outer medulla is decreased, nevertheless the sodium 
delivery to thick ascending Limb of Henle is increased due to osmotic diuresis of CM but 
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the low oxygen pressure in this part of nephron is not related to the osmolality of CM (Liss 
etal., 1998). Administration of A1 adenosin receptor antagonists could not humiliate the 
decreased oxygen tension (Liss etal., 2004), but it seems that prostaglandins and nitric oxide 
could counteract vasoconstrictor effect of CM (Agmon etal., 1994). In animals, nitric oxide 
depletion has an effective role in vasoconstriction (Agmon etal., 1994; Ribeiro etal., 2004).  
3.2 Reactive oxygen species 
The role of oxidative stress in pathogenesis of Ischemia/reperfusion injuries is well known. 
Activation of oxidative stress processes in ischemia produce reactive oxygen species (ROS) 
which have a known role in AKI. The diseases which are considered as risk factors of CIN 
(CKD, CHF, and Diabetes) are associated with high oxidative stress state.  
Experimental studies demonstrated that therapeutical strategies reduce the production of 
ROS and/or increase the nitric oxide activity and by these mechanisms halt the renal 
injuries due to Ischemia in different models of AKI including CIN.  The rational use of 
antioxidants such as acetylcystein or allopurinol in preventing CIN is to lower or inhibit the 
oxidative stress processes. 
3.3 Direct cytotoxicity 
It is not known how much physicochemical properties of Iodinated CM are responsible for 
CIN and whether direct cytotoxicity of CM play any role in pathogenesis of CIN or not. In 
vitro studies showed that CM particularly HOCM is cytotoxic to mesangial and tubular cells 
(Itoh etal., 2006; Peer etal., 2003). The mechanism of such cytotoxicity is not known, but 
possibly cellular energy failure, disintegration of calcium homeostasis, apoptosis 
mechanisms and oxidative stress play a role (Beeri etal., 1995; Haller & Hizoh, 2004; Humes 
etal., 1987;). Internalization of non-ionic agents are seen in proximal tubules, (nephrosis 
osmotic), but these pathologic findings are also seen in patients who take CM without renal 
function deterioration (Persson & Tepel, 2006).CM may cause vasoconstriction by direct 
action on smooth muscles of arteries. More studies, should be run to show the relation of 
these changes with iso-osmolal contrast agents. 
3.4 Others 
In experimental studies CM can decrease capillary blood flow by decreasing the velocity of 
erythrocytes and increasing the red blood cells aggregation. HOCM also decreases 
erythrocyte volume and alters its membrane deformability. Recently hemeoxygenase 
activator is introduced as a pathomechanism of CIN development. Hemeoxygenase inhibits 
ROS production, suppresses pro-apoptotic proteins, activate anti-apoptotic proteins and has 
anti-inflammatory and vasodilatory effects. In future this enzyme may play an important 
role in CIN prophylaxis in human. 
4. Prophylaxis 
If CIN happens, the management is supportive, and because the time of insult is known the 
best measure is prophylaxis. Although in many studies, meta-analysis and systematic 
reviews have focused on prophylactic measures of CIN, nevertheless there is no an 
evidence-based guideline for clinical use. 
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No general consensus is present about the prophylactic measures of CIN other than 
stopping nephrotoxic agents, hydration and use of the lowest possible volume of CM and 
not using HOCM. Published guidelines are according to limited studies on very heterogenic 
patients. So they cause more confusion rather than better understanding and enlightment of 
the issue of CIN to provide the best reliable prophylactic measures. Probably the European 
Society of Urogenital Radiology (ESUR) guideline is yet valid (Morcos etal.,1999) and 
further studies within last 13 years have not been demoted its validity. 
4.1 Volume expansion 
Theoretically, volume expansion suppresses renin-angiotensin system activity, decreases 
vasoconstrictor hormones like endothelin, increases sodium diuresis, inhibits tubulo-
glomerular feedback, prevents tubular obstruction, protects cells against ROS and finally 
dilutes the CM in tubules. Overall the toxicity of CM is decreased on tubules by hydration.  
Large numbers of studies are about the role of volume expansion in preventing CIN. No 
controversy is present about the effectiveness of volume expansion. Up to now the volume 
expansion is known as the most effective measure in nephroprotection of CIN (Thomsen, 
2006).This benefit has been shown in many randomized controlled trials (Bader etal.,2004; 
Dussol etal., 2006; Merten etal., 2004; Mueller etal., 2002; Taylor etal, 1998; Trivedi etal., 
2003). But it is difficult to show that which type of fluid in how much dose and at which 
time is more suitable (McCullough & Soman, 2005). This obscurant is due to the 
heterogeneity of the studies and different definitions for CIN are used. Unfortunately these 
studies rarely reported the hard clinical endpoints.  
Solomon et al has done the first randomized controlled trials (RCT) in this regard (Solomon 
etal., 1994). They showed that forced diuresis with diuretic or manitol is worse than 
hydration with isotonic salin or 0.45% salin. This Study did also very clearly show that 
volume expansion is highly effective in prevention of CIN in high risk patients and since 
then this prophylactic measure is the key stone of CIN prevention. Intravenous fluid 
therapy is also superior to oral hydration (Weisbord & Pavelsky, 2008) as it was shown in 
the study of Solomon etal .They reported that the control group had had 10 times more CIN 
than case controls. Because of such significant difference, this study was stopped early. 
Mueller etal also showed superiority of isotonic saline to 0.45% salin in patients with normal 
renal function, but if renal failure is present, there is no difference between two types of 
fluids (Mueller etal., 2002). The study of Merten etal compared sodium bicarbonate with 
isotonic saline in preventing CIN. Although this study showed better results with 
bicarbonate, but the study is criticized in different aspects (Merten etal., 2004).  
In some studies intravenous bolus of isotonic saline just before procedure, or oral hydration 
from the night before the procedure, or use of NaCl tablets from 2 days before contrast 
exposure were examined with different results. (Bader etal.,2004; Dussol etal., 2006; Taylor 
etal, 1998; Trivedi etal., 2003) Volume expansion with isotonic saline is safe, simple and 
cheap, but not all patients taking CM will unfortunately suffer it. We showed that in 
patients that use of isotonic salin may be associated with the hazard of overload, use of 
0.45% salin may be as effective as isotonic salin (Vasheghani-Farahani etal., 2010). It has 
been demonstrated that 26% of high risk patients have not been received any kind of 
intravenous fluid, and there was no standard about the volume and the type of fluid that 
were being used in the remaining patients. Urine volume more than 150cc / hour is shown to 
be a good sign of decreased risk of CIN (Stevens etal., 1999). Cardiologists are the main 
target group who should know and use the strategies of volume expansion.  
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4.2 Sodium bicarbonate 
The mechanism of sodium bicarbonate in preventing CIN is not clearly understood. 
Theoretically Sodium bicarbonate can expand the extracellular volume. 
Alternatively it has been suggested that sodium bicarbonate will decreased the amount of 
ROS by increasing the PH of medulla. So the kidney will be protected from oxidant injuries 
(Atkins, 1986; Bakris etal., 1990; Merten etal., 2004; Morcos etal., 2005; Weisbord etal., 2008). 
Through this line of explanation, the main protective effect of sodium bicarbonate is not 
through volume expansion.  
There are many concerns about the role of bicarbonate in prevention of CIN (Briguori etal., 
2007; From etal., 2008; Masuda etal., 2007; Ozcan etal., 2007, Recio-Mayoral etal., 2007).Most 
studies compared isotonic saline and sodium bicarbonate have reported contradictory 
results. Masuda etal., showed Bicarbonate is more effective than saline in prevention of CIN 
(1.7% Vs 13%) (Masuda etal.,2007). In a meta-analysis, comparing saline and bicarbonate, it 
was shown that rise of serum creatinine in bicarbonate group is less than salin group, but in 
term of need to dialysis and death there was no difference between the two groups(Hogan 
etal., 2008).In the largest RCT comparing salin and bicarbonate, No differences between two 
groups was shown (Maioli etal., 2008). In another retrospective study including 7977 
patients it was shown that the risk of CIN in sodium bicarbonate is significantly higher than 
salin group (From etal., 2008).We showed that addition of sodium bicarbonate to isotonic 
salin added no benefit to isotonic salin alone in preventing CIN (Vasheghani-Farahani etal., 
2009).These controversial results and heterogeneity of studies make it difficult to be able to 
extract a conclusion that bicarbonate is even equal to salin in preventing CIN.  
4.3 N-Acetyl Cysteine (NAC) 
The main mechanism of NAC may be due to its known antioxidant peculiarity. It may 
diminish the oxidative stress markers ((Drager etal., 2004; Efrati etal., 2003) and / or its 
vasodilatory effect (Fishbane etal., 2004; Stenstorm etal., 2008).CM decrease urinary nitric 
oxide and NAC may inhibit this effect of CM. But it has been shown that NAC has no effect 
on F2- isoprostane a known marker of oxidative stress (Efrati etal., 2003).  
NAC has wide first-pass metabolism, so its bioavailability will be very low if it is 
administered orally. Meanwhile many centers use oral NAC without any evidence-based 
guidelines (Marenzi etal., 2006b).  The drug has also wide intra-patient variation. Its half-life 
after intravenous injection is 40 minutes. It has wide plasma and tissue protein binding. 
After oral or intravenous administration of NAC the drug cannot be detected in systemic 
circulation. So its effectiveness may be due to secondary effects like induction of glutathione 
synthesis rather than its direct effect. Because there are no tool to measure these secondary 
effects, no optimal dose of NAC can be defined and the dose of drug for prevention of CIN 
is empirical.  
Clinically the use of NAC was controversial from the early time. Positive and negative 
results about NAC have created confusions about the role of this agent in CIN prophylaxis 
protocols. When the first report of NAC was published by Tepel and his coworkers (Tepel 
etal., 2000), it caused a universal trend to use NAC in all patients have been taking CM. 
They showed significant decrease in the rate of CIN in patients on NAC (2% Vs 12%). Since 
then many studies have been conducted with contradictory results. Now After 12 years of 
use of NAC in prevention of CIN, there is no general consensus about this pharmacological 
agent. In last decade many RCTs, non-randomized studies and meta-analyses were 
performed with NAC (Alonso etal., 2004; Bagshaw etal., 2006, Bagshaw & Ghali, 2004; Birck 
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etal., 2003; Duong etal., 2005; Dzgoeva etal., 1995, Isenbarger etal., 2003; Kshirsagar etal., 
2004; Liu etal., 2005; Nallamothu etal., 2004; Onbasili etal., 2007; Pannu etal., 2004; Spargias 
et al., 2004; Zagler etal., 2006). Some of these studies showed that there is no positive effect 
for NAC in prevention of CIN (Onbasili etal., 2007; Spargias et al., 2004). On the other hand 
some meta-analyses showed effectiveness of NAC but the most of these meta- analyses had 
inconclusive results (Bagshaw etal., 2006; Nallamothu, 2004). In conclusion although huge 
data is available, the role of NAC in preventing CIN is moot yet. This discrepancy may be 
due to bias in the publishing of studies with positive results, so these studies should be 
considered with skepticism (Fishbane etal., 2008).  
In a study on patients with myocardial infarction high dose intravenous NAC (1200mg) was 
effective in prevention of CIN (Marenzi etal., 2006b). Surprisingly no patient in this study 
had received fluid for volume expansion. An interesting but confusing issue in studies about 
NAC is the decrement of serum creatinine after CM exposure (Baker etal., 2003; Drager etal., 
2004; Kay etal., 2003; Marenzi etal., 2006b). Probably NAC can decrease serum creatinine 
directly without affecting renal function (Drager etal., 2004). In this study the GFR of 
patients who were taken NAC four days before CM exposure was significantly higher than 
those patients were taken NAC only for two days. Interestingly this study and study of 
Hoffmann and coworkers showed that NAC may decrease serum creatinine in patients that 
had not received CM (Hoffmann etal., 2004). There are concerns that NAC with increasing 
tubular secretion of creatinine decreases the serum creatinine without any change in GFR. A 
recent meta-analysis found that NAC was more protective than saline infusion and the 
authors recommended the use of NAC because of its low cost, availability and paucity of 
side effects (Cigarroa etal., 1989). In contrast to this recommendation which is based on 
safety of the NAC, there is a report of anaphylactic reaction in 3-6% of patients receiving 
intra-venous NAC (Kanter, 2006). 
Briefly, NAC may increase GFR in normal patients and restore GFR in high risk patients for 
CIN. But it is not known whether these effects are due to direct protective effect of NAC on 
kidney or it is due to alteration in creatinine metabolism. Some studies reported good effect 
of NAC while others did not find such positive effects. 
In conclusion, there is no agreement about the NAC. Otherwise there is no guideline about 
the route of administration of NAC or the dose or the time of its administration. There is an 
important question whether its effect on serum creatinine is real or spurious. It is obvious 
that we need more good designed RCTs to solve these controversies.   
4.4 Type and dose of Contrast Media 
It is obvious that HOCM is associated with higher risk of CIN. So for prophylactic purposes 
it is recommended not to use this type of CM in any patients particularly in the patients 
with moderate or high risk of CIN. In analysis of present studies about the type of contrast, 
it is possible that different monomer CM have different toxic effects (Bettmann, 2005; 
Solomon etal., 2005). Up to now there is no evidence that CIN is more prevalent with LOCM 
than IOCM. There is a trend to use Iodixanol which is a dimeric IOCM (Barrett & Carlisle, 
1993). But different studies showed no superiority of this agent over the other IOCM or 
LOCM (Baker etal., 2003; Boccolandro etal., 2003; Briguori etal., 2005). Over all, it seems that 
there is no difference between LOCM and IOCM in regard of CIN. 
The other issue in preventing measures for CIN in the term of CM is the dose of the agent. 
So it is advised that the lowest possible dose of the CM should be administered in patients at 
risk of CIN. It is obvious that the higher the volume of the CM is associated with the higher 
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incidence of CIN (Cigarroa etal., 1989; Manske etal., 1990), but there is no magical dose of 
contrast to believe that below that dose, the CIN will not occur. The renal function is an 
important limiting factor for dose of CM. In study of Laskey etal. it was reported that if the 
volume of CM exceeded 3.7 times of creatinine clearance, the risk of CIN will be higher 
(Laskey eal., 2002). So the absolute value of contrast volume may be too low. There are 2 
formulas for calculating relatively the safe volume of CM according to renal function. 
 dose of CM 
5       
 
 ( )
ml
contrast media
kg
mg
serumcreatinine
dl
  (1) 
Or, 
 
300         
 
mlcontrast media
serumcreatinine
  (2) 
In any case the dose of contrast should not be exceeded by 300 ml. For IOCM and LOCM the 
dose may increase by 1.5 times. 
4.5 Other preventive strategies 
Several studies examined different pharmacologic agents to prevent CIN.  Studies about 
fenoldopam, dopamin, calcium channel blockers, atrial natriuretic peptide, L-arginine and 
statines   are inconclusive. Use of ATP-MgCl2 also failed to show beneficial effect. Mesna is 
another pharmacologic agent that can inhibit ROS related renal injury. 
4.5.1 Theophylin 
High level of adenosin is a possible mechanism for occurrence of CIN. It causes afferent 
arteriole vasoconstriction (Haller etal., 2004; Pflueger etal., 2000). Theophylin is a non 
specific antagonist of adenosin receptor, so it may theoretically be beneficial. Studies about 
the theophylin like studies of NAC are not conclusive. Few studies showed effectiveness 
of theophylin or aminophylin in prevention of CIN , but in a meta-analysis no positive effect 
of this drug was shown (Bagshaw & Ghali, 2005). So the routine use of theophylin is not 
recommended. In a study on patients in ICU, infusion of 200mg theophylin half an hour 
before contrast exposure was superior to NAC (Huber etal., 2006) but arythmogenesity of 
theophylin is a problem in coronary artery disease. It is possible that in the future, 
theophylin is replaced by a selective adenosin receptor antagonist with less toxicity and 
more effectiveness than theophylin in CIN prophylaxis protocols (Pflueger etal., 2000). 
4.5.2 Prostaglandin analogues 
Prostaglandin I1 and E1 may have some protective effects , but it is associated with severe 
hypotension. So their routine use is not suggested. Prostacyclin may also have such a role.  
4.5.3 Ascorbic acid 
Studies about the ascorbic acid are inconclusive (Briguori etal., Spargias etal., 2004). 3 grams 
of ascorbic acid 2 hours before contrast exposure and 2 grams at night and in the morning 
after procedure may decrease the risk of CIN (Spargias etal., 2004). 
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4.5.4 Trimetazidine 
This novel pharmacologic agent interferes with different metabolic pathways. It can prevent 
Ischemia-reperfusion injuries. In a RCT it was effective in preventing CIN (Onbasili etal., 
2007). 
4.5.5 Erythropoietin 
Erythropoietin may have some role in CIN prophylaxis. Its effect has been shown in some 
studies (Yokomaku etal., 2008).  
4.6 Renal replacement therapy 
The rationality for use of renal replacement therapy after contrast exposure is to remove the 
CM rapidly to prevent CIN (Frank etal., 2003; Marenzi etal 2003,2006b; Vogt, 2001).Each 
session of dialysis can remove 60-90% of administered CM (Deray etal., 2006). CM are 
totally eliminated by the kidneys. They are handled by the kidneys like Inulin. Different 
extracorporeal techniques can efficiently remove CM. So it is rational to use these techniques 
just after contrast exposure to prevent or reduce the risk of CIN. Recent study on severe 
CKD patients not on dialysis(GFR less than 15ml/min) comparing isotonic salin and 
prophylactic hemodialysis showed that patients on hemodialysis were discharged from the 
hospital while 5% of them need hemodialysis. Meanwhile, the rate of chronic dialysis at the 
time of discharge in salin group was 45% (Solomon etal., 2004). Nevertheless, other studies 
demonstrated that hemodialysis in patients with previous history of renal failure was not 
beneficial and the incidence of CIN will not be changed by this modality (Deray, 2006; Vogt, 
2001).One meta-analysis has supported this result (Cruz etal., 2006). Patients on dialysis do 
not also need dialysis after contrast exposure (Hamani etal., 1998; Morcos etal., 2002). 
 Only few study reported the prophylactic usefulness of hemodialysis (Lee etal., 2007;  
McCullough & Soman, 2005). But repeatedly it has been shown that hemodialysis has no 
role in preventing CIN (Cruz etal., 2006; deray, 2006; Marenzi etal., 2006b). In contrast to 
positive studies one RCT showed that prophylactic dialysis caused more reduction of renal 
function and these patients need more dialysis after exposure to contrast (Vogt etal., 2001). 
In one meta-analysis (Cruz etal., 2008), the beneficial effect of pre-procedural extracorporeal 
blood purification was obscure. 
It has been shown that serum creatinine four days after contrast exposure is less in dialysis 
group, but this difference was not significant.  
CRRT, hemodiafiltration (CVVHD) and hemofiltration are also evaluated in this regard 
(Gabutti etal., 2003, Marenzi etal., 2003). The only technique with enthusiasm was CVVH. 
But this procedure is very complex and expensive and even if further studies prove its 
efficacy in large clinical trials, it cannot be ordinarily used in clinic (Klarenbach etal., 2006).  
Overall, given the cost and logistic necessity of extra corporeal modalities, it is difficult to 
suggest routine use of these techniques in prophylactic protocols of CIN and further studies 
may show its advantage or disadvantage. 
4.7 Drugs which should be stopped before procedure 
At the time of planning for procedures with CM, all drugs which are taken by patients 
should carefully be reviewed. There is no RCT about the harmfulness of drugs, but 
generally speaking the following drugs may be associated with increased risk of CIN. 
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4.7.1 Non-Steroid Anti-Inflammatory Drugs (NSAIDs)  
Case reports and clinical experiences have shown that NSAIDs may increase the incidence 
of CIN. There is no difference between selective or non selective cycloxygenase inhibitors. 
They should be stopped several days before procedure. 
4.7.2 Antihypertensive agents 
No antihypertensive drug is contraindicated for patients that undergo for imaging with CM. 
But if they cause hypotension, the risk of CIN may be increased. The use of angiotensin 
converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) should not 
be stopped (Erley, 2006). Although In patients with serum creatinine 2 mg/dl or higher it 
may increase the rate of CIN. Cirit etal.  have reported an increased risk of CIN with ACEIs 
(Cirit etal., 2006), nonetheless another study showed its preventive effect (Dangas etal., 
2005).There is also a report that Captopril may cause decrease in incidence of CIN in 
diabetic patients(Gupta etal., 1999). 
There is no study about ARBs. 
4.7.3 Metformin 
Metformin causes lactic acidosis in patients with renal failure. Otherwise uncontrolled 
diabetes is a risk factor of CIN. There is no RCT about metformin and CIN. It is 
recommended to continue the use of the drug until the night before the procedure (Bailey 
etal., 1996). Others have suggested the continuation of metformin in patients with normal 
renal function. If metformin is stopped, it is better to start it again when the physician is sure 
that CIN has not been happened. 
4.7.4 Diuretics 
Use of furosemide, manitol and endothelial receptor antagonists were associated with 
increased risk of CIN (Anto etal., 1981; Solomon etal., 1994; Weisberg etal., 1994).Forced 
diuresis increases the risk of CIN. Although there is no RCT about diuretics, nevertheless it 
is not theoretically rational to expand the volume from one hand and to contract it from the 
other hand. So it is recommended to discontinue diuretics 12 hours before the procedure 
and to restart it 24 hours after that. 
4.7.5 Manitol 
Like diuretics it may increase the risk of CIN in patients with forced diuresis (Solomon etal., 
1994). The problem is raised in neurosurgical patients on manitol. It is suggested to stop the 
drugs several hours before CM administration and to monitor the hydration status of the 
patients very carefully (Erley, 2006) 
5. Tools for assessment of patients at risk of CIN 
In published study there is no controversy about the risk factors of CIN. But nearly all 
patients undergoing imaging with CM have more than one risk factor, so the investigators 
are looking for an innovative risk stratification model to detect the patients who are at a 
higher risk of CIN. There are different scoring tools that could detect the patients at risk of 
CIN before the procedure and accordingly the physicians can provide and modify the 
different preventive measures for these patients to decrease the risk of CIN.  
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Up to the present time there are two popular scoring models. Both of which have been 
introduced at 2004 and provide good tools for estimating the odds of the CIN. They are 
more or less similar with few differences in the terms of risk factors and scoring. According 
to the data of 8357 PCI patients, Mehran et al. determined the independent predictive factors 
of CIN and provided a scoring model for estimating potential risk of patients (Mehran etal., 
2004). Bartholomew et al. also suggested another risk stratification model at the same year 
(Bartholomew etal., 2004). They evaluated the data of 2047 patients and determined the risk 
factors and their risk scoring. Table 3 shows these two models comparatively. 
According to Mehran's model the risk score of less than 5 is associated with 7.2% risk of CIN 
and nearly no patients need dialysis (0.04%) but risk score more than 16 will increase the 
risk of CIN up to 57.7% and need to dialysis to 12.6%. 
 Bartholomew et al. reported no patients with risk score of less than 1 developed CIN and 
CIN had occurred in 25% of patients with risk score more than 9. 
In regards to risk stratification models, some factors are not predictable before the procedure 
(like need to balloon pump or volume of contrast), so according to these models it is 
impossible to estimate the exact reliable and accurate risk of CIN in every patient. 
 
Mehran model Bartholomew model 
Risk factor Point Risk factor point 
Hypotension(BP<80 mmHg)   5 Hypotension 1  
CHF 4 CHF 1 
Intra-aorta balloon pump 5 Intra-aorta balloon pump 2 
Diabetes 3 Diabetes 1 
Volume of contrast 1(/ each100cc) Volume of contrast(>260cc/) 1 
Previous CKD:  
Serum Creatinine> 132 mmol/L 
Or: 
GFR 40-60 ml/min 
GFR 20-40 ml/min 
GFR <20 ml/min 
 
4 
 
2 
4 
6 
Creatinine clearance<60ml/min 2 
Anemia 3 Peripheral vascular disease 1 
Age > 75 years 4 Emergent PCI 2 
Table 3. Two most popular risk starfication models of cin 
6. Recommendations 
Until more accurate and universally accepted guidelines are developed, following 
recommendations which are based on different studies are useful in preventing CIN.The 
important issue is how to find the patients at risk before imaging procedures. There are 
some recommendations in this regard. 
The American Radiology College (ARC) has suggested the measurement of serum creatinine 
in all patients who are suspected of having renal disease or those at risk of nephrotoxicity 
before the procedure (The committee on drugs and contrast media of the American College 
of Radiology, 2010). The patients at risk are those with a positive answer to any of the 
following statements: history of renal disease (including tumor or transplantation), familial 
history of renal disease, on diabetes therapy, having paraproteinemia disorders, having 
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collagen vascular disease, taking specific drugs such as metformin or NSAIDs or 
Nephrotoxic antibiotics. The ESUR has also recommended to measure serum creatinine in 
some specific patients (Thomsen & Morcos, 2005). Accordingly, the patients with a history 
of renal disease, renal surgery, proteinuria, hypertension, diabetes, gout, recent use of 
nephrotoxic drugs are considered high risk patients. The Urogenital Radiology Association 
also suggests that serum creatinine should be measured in all patients with history of 
chronic renal failure or those who are candidates for intra-arterial angiography or patients 
with at least one positive answer to the questioner (Thomsen & Morcos, 2006). 99% of 
patients with negative answers to all questions had serum creatinine less than 1.7 mg/dl 
(Thomsen, 2005).A good alternative surrogate marker to the serum creatinine is to measure 
GFR according to one of the MDRD formulas in all patients with any risk factors of CIN, 
because the serum creatinine has limitation to find CKD patients. 
After finding the high risk patients there are some different preventive measures for people 
at different risks. But some general recommendations should be taken into account for all 
patients whether they have risk factor(s) or not. 
6.1 General recommendations for all patients taking CM 
1. Evaluation of risks in all patients planned to take CM. 
2. Measurement of serum creatinine in all high risk patients before and after 
procedure. 
3. List the risk factors according to present risk score models. 
4. Encouraging all patients to drink water before procedure. 
5. All patients should be taken LOCM or IOCM. 
6. The dose of CM should be as low as possible.  
7.  Continuing use of angiotensin converting enzyme inhibitors and angiotensin receptor 
blockers is not contraindicated  
8. NSAIDS should be stopped several days before procedure. 
9. Use of furosemide and manitol should be stopped 12-24 hours before CM 
administration. 
10. Stop metformin the night before procedure until ensure of not happening CIN. 
11. No repetition of procedure until to be sure that CIN has not been developed. 
6.2 Recommendations for low risk patients 
(Normal renal function and risk score≤5 according to Mehran's score) 
1. All recommendations for no risk patients 
2. Oral hydration (at least 500cc pre-procedure and 2500cc within 24 hours post 
procedure) 
3. Intravenous isotonic salin in patients who are not taking oral intake at rate of 1 
ml/kg/hour starting 4 hours before procedure and continuing at least for 6 hours post 
procedure . It is best to continue the hydration for 24 hours after procedure. 
4. No repetition of procedure until serum creatinine returns to base value. 
6.3 Recommendation for moderate risk patients 
(Patients with CKD1-3 and/or risk score 5-15 according to Mehran's score) 
1. All recommendations for low risk patients 
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2. Delaying the procedure in volume depleted patients or those who have blood 
circulation collapse or patients with CHF until stability of hemodynamic is achieved. 
3. Infusion of 0.45% salin in patients at risk of volume overload. 
4. If the time to procedure is less than 6 hours (in emergent angiography) a simultaneous 
administration of oral and IV Fluid with the dose of 3 ml/kg/hour and maximum 300cc 
fluid/hour is recommended. The fluid administration should be started one hour 
before procedure. After procedure the fluid is continued with the rate of 1 ml/kg/hr for 
12 hours. 
5. Use of NAC 1200mg twice daily in the day and day after the procedure. In emergency 
situations use of 1200mg intravenous bolus of NAC instead of first oral dose is 
appropriate. 
6. Measurement of serum creatinine 24-48 hours after procedure in patients with 
moderate and severe risk factors 
6.4 Recommendations for high risk patients 
(CKD4-5 and/or risk score >15 according to Mehran's score) 
1. All recommendations in moderate risk patients 
2. Nephrology consultation 
3. Use of hydration should be individualized according to volume status of each patient 
with considering overload hazards. 
4. In ICU patients use of 200mg theophylin 30minutes before procedure, particularly if 
hydration protocol could not completely be follow. But remember the side effects of this 
drug.  
7. Anaphylactic reactions 
Anaphylactic reactions to CM are well known from the early use of these agents. These 
reactions are dermal allergic type reactions, edema, pulmonary edema, angina pectoris, 
arrhythmia and hypertension crisis. Mostly these side effects are mild and there is no need 
to treatment. The occurrence of the serious side-effects is within 20 minutes of CM 
administration. They are exhibited by nausea and vomiting, urticaria, pulmonary edema, 
bronchospasm, laryngospasm, hypotension, tachycardia, vaso-vagal responses and seizure.      
 In last decade the reactions to CM have significantly decreased from 5-12% to 0.2-0.7% 
(Sayol & Bush, 2011). It may be due to shift from HOCM to LOCM and IOCM. Anaphylactic 
reaction to HOCM is more than LOCM.  Ionicity is also a cause of reaction to these agents 
and nonionic monomers are less anaphylactic. These reactions are either chemotoxic or 
Anaphylactic (Idio or nonidiosynchratic).The chemotoxic reaction is related to 
physicochemical property of CM and its severity is dependent on the dose and 
concentration of the agent. 
The mechanisms of anaphylactic reaction are not well understood. Histamine, Leukotriens, 
Basophiles and prostaglandins may be mediators of this type reaction. It is unlike that 
antigen- antibody interaction plays any role. 
Aging, history of allergy and asthma and previous history of reaction to CM, are the risk 
factors of anaphylactic reactions. The patients with CKD, cardiovascular disease and 
epilepsy are also at increased risk. Beta blockers may increase the threshold and severity of 
anaphylactic reactions (Kadivar & McClennan, 2010). 
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Treatment of anaphylactic reactions is mostly supportive. In mild reactions anti histaminic 
drugs are effective, but in more severe cases use of short acting steroids is mandatory and 
even some critical care facilities may be necessary.  
8. Alternatives to Contrast Media 
Very high risk patients may be in need for other imaging techniques rather than using 
contras media. One of these agents is Carbone dioxide which may be a good alternative to 
iodinated CM. It may be used solely or in conjunction with low dose of iodinated CM. The 
procedure is simple and the quality of images is good. With using modern technologies such 
as digital subtract angiography the nephrotoxicity of this method is neglectable (Kessel etal., 
2002; Liss etal., 2005; Shaw & Kessel, 2006).  
The other alternative is magnetic resonance angiography (MRA). Its main complication in 
renal failure is nephrogenic systemic fibrosis (NSF). SO in patients with moderate to severe 
renal failure it is contraindicated and in patients with mild renal failure its use is cautiously 
recommended.  
9. Conclusion 
Contrast agents are associated with many complications. There are two more prevalent and 
important complications related to contrast media: allergic reactions and CIN. The allergic 
reactions are preventable by knowing the high risk patients and premedication with steroids 
and antihistamines. 
The most important complication of contrast agents is CIN, which is usually a mild to 
moderate AKI that is rapidly recovered. But it could be associated with increased significant 
morbidity and mortality. There is no treatment for developed CIN, so it should be 
prevented by some measures. The proved modalities for prevention of CIN are saline 
administration, the lowest possible dose of CM, and use of IOCM or LOCM. 
All patients at risk should be evaluated carefully before the procedures with CM and the 
risk factors should be stratified according to available risk stratification models. 
10. References 
Agmon Y, Peleg H, Greenfeld Z, etal. (1994) Nitric oxide and prostanoids protect the  renal 
outer medulla from radiocontrast toxicity in the rat. J Clin Invest; 94: 1069–1075. 
Alonso A, Lau J, Jaber BL, et al. (2004) Prevention of radiocontrast nephropathy with N-
acetylcysteine in patients with chronic kidney disease: a meta-analysis of 
randomized, controlled trials. Am J Kidney Dis; 43:1–9. 
American Heart Association statistics committee and stroke subcommittee -2007 update: A 
report from the AHA statistics committee and stroke subcommittee. Circulation 
115:e69-e171. 
Anto HR, Chou SY, Porush JG, Shapiro WB. (1981) Infusion intravenous pyelography  and 
renal function. Effect of hypertonic mannitol in patients with chronic renal 
insufficiency. Arch Intern Med;141:1652–1656 
Arakawa K, Suzuki H, Naitoh M, etal. (1996)Role of adenosine in the renal responses  to 
contrast medium. Kidney Int; 49:1199–1206. 
www.intechopen.com
 
Advances in the Diagnosis of Coronary Atherosclerosis 
 
140 
Araujo M, Welch WJ. (2006) Oxidative stress and nitric oxide in kidney function. Curr Opin 
Nephrol Hypertens; 15:72–77. 
Aspelin P, Aubry P, Fransson SG, etal. (2003)Nephrotoxic effects in high-risk patients 
undergoing angiography. N Engl J Med;348:491–499. 
Atkin JL. Effect of sodium bicarbonate preloading on ischemic renal failure. Nephron 
1986;44:70–76. 
Bader BD, Berger ED, Heede MB, et al. (2004) What is the best hydration regimen to prevent 
contrast media-induced nephrotoxicity? Clin Nephrol; 62:1–7. 
Bagnis C, Idee JM, Dubois M, et al. (1997) Role of endothelium-derived nitric oxide 
endothelin balance in contrast medium-induced acute renal vasoconstriction in 
dogs. Acad Radiol; 4: 343–348. 
Bagshaw SM, Ghali WA. (2004) Acetylcysteine for prevention of contrast-induced 
nephropathy after intravascular angiography: a systematic review and meta-
analysis. BMC Med; 2:38–49. 
Bagshaw SM, Ghali WA. (2005) Theophylline for prevention of contrast-induced 
nephropathy: a systematic review and meta analysis. Arch Intern Med; 165: 1087–
1093. 
Bagshaw SM, McAlister FA, Manns BJ, Ghali WA. (2006)Acetylcysteine in the prevention of 
contrast-induced nephropathy:A case study of the pitfalls in the evolution of 
evidence. ArchIntern Med;166:161–166. 
Bailey CJ, Turner RC. Metformin. N Engl J Med; 334:574–579. 
Baker CS, Wragg A, Kumar S, etal. (2003) A rapid protocol for the prevention of 
contrastinduced renal dysfunction: the RAPPID study. J Am Coll Cardiol; 41:2114–
2118. 
Bakris GL, Burnett JC Jr. (1985) A role for calcium in radiocontrast induced reductions in 
renal hemodynamics. Kidney Int; 27:465–468. 
Bakris GL, Lass N, Gabaer AO, etal. (1990) Radiocontrast medium-induced declines in renal 
function. A role for oxygen free radicals. Am J Physiol; 175:57–60. 
Barrett BJ, Parfrey PS, Vavasour HM, et al. (1992) Contrast nephropathy in patients with 
impaired renal function: high versus low osmolar media. Kidney Int;41: 1274– 1279. 
Barrett  B J,Carlisle E J. (1993) Meta-analysis of the relative nephrotoxicity of high- and low 
osmolality iodinated contrast media . Radiology;188:171-178. 
Barrett BJ, Katzberg RW, Thomsen HS, et al.( 2006) Contrast-induced nephropathy in 
patients with chronic kidney disease undergoing computed tomography: A  double 
blind comparison of iodixanol and iopamidol. Invest Radiol;41:815–821. 
Bartholomew BA, Harjai KJ, Dukkipati S, et al.(2004). Impact of nephropathy after 
percutaneous coronary intervention and a method for risk stratification. Am J 
Cardiol; 93:1515–1519. 
Beeri R, Symon Z, Brezis M, et al. (1995) Rapid DNA fragmentation from hypoxia along the 
thick ascending limb of rat kidneys. Kidney Int; 47: 1806–1810. 
Bettmann MA. (2005)Contrast medium-induced nephropathy: critical review of the  existing 
clinical evidence. Nephrol Dial Transplant;20(suppl 1): i2–i7. 
Birck R, Krzossok S, Markowetz F, et al. (2003) Acetylcysteine for prevention of contrast 
nephropathy: meta-analysis. Lancet; 362:598–603. 
www.intechopen.com
 
Risks and Complication of Coronary Angiography: Contrast Related Complications 
 
141 
Boccolandro F, Amhad M, Smalling RW, Sdringola S. (2003) Oral acetylcysteine does not 
protect renal function from moderate to high doses of intravenous radiographic  
contrast. Cathet Cardiovasc Interv; 58:336–341. 
Briguori C, Airoldi F, D’Andrea D, et al. (2007) Renal insufficiency following contrast media 
administration trial (REMEDIAL): a randomized comparison of 3 preventive 
strategies. Circulation; 115:1211–1217. 
Briguori C, Colombo A, Airoldi F et al. (2005) Nephrotoxicity of low-osmolality versus iso-
osmolality contrast agents: impact of N-acetylcysteine. Kidney Int;  68:2250–2255. 
Briguori C, Visconti G, Rivera N V, etal.( 2010) Cystatin C and contrast-induced acute 
kidney injury. Circulation;121:2117-2122. 
Carraro M, Malalan F, Antoinione R, et al.( 1998) Effects of a dimeric vs. a monomeric 
nonionic contrast medium of renal function in patients with mild to moderate renal 
insufficiency: a double-blind randomized clinical trial. Eur Radiol; 8:144– 147. 
Cigarroa R G, Lange R A, Williams R H, Hillis L D. (1989) Dosing of contrast material to 
prevent contrast nephropathy in patients with renal disease. Am J Med  ;86: 649-652. 
Cirit M, Toprak O, Yesil M, et al. (2006) Angiotensin-converting enzyme inhibitors as a risk 
factor for contrast-induced nephropathy. Nephron Clin Pract; 104: c20- c27. 
Costa N. (2004) Understanding contrast media. J Infus Nurs; 27:302–12. 
Cruz D N, Perazella M A, Bellomo R, etal. (2006) Extracorporeal blood purification therapies 
for prevention of radiocontrast-induced nephropathy: A systematic review. Am J 
Kidney Dis; 48:361-371. 
Dangas G, Iakovou I, Nikolsky E, et al. (2005) Contrast-induced nephropathy after 
percutaneous coronary interventions in relation to chronic kidney disease and 
hemodynamic variables. Am J Cardiol; 95:13–19. 
Deray G. (2006) Dialysis and iodinated contrast media. Kidney Int Suppl;100:S25–S29. 
Drager LF, Andrade L, Barros de Toledo JF, etal. (2004) Renal effects of N- acetylcysteine in 
atients at risk for contrast nephropathy: decrease in oxidant stress-mediated 
renaltubular injury. Nephrol Dial Transplant; 19:1803–1807. 
Duong MH, MacKenzie TA, Malenka DJ. (2005) N-acetylcysteine prophylaxis 
significantlyreduces the risk of radiocontrast-induced nephropathy: comprehensive 
meta-analysis. Catheter Cardiovasc Interv; 64:471–479. 
Dussol B, Morange S, Loundoun A, et al. (2006) A randomized trial of saline hydration to 
prevent contrast nephropathy in chronic renal failure patients. Nephrol Dial 
Transplant; 21:2120–2126. 
Dzgoeva FU, Milovanov Iu S, Kutyrina IM. (1995) Acute kidney failure related to the use of 
x-ray contrast agents and indomethacin: the risk factors and mechanisms of its              
development. (Abstract)Ter Arkh; 67:36–39. 
Efrati S, Dishy V, Averbukh M, etal. (2003) The effect of N-acetylcystein on renal function,               
nitric oxide, and oxidative stress after angiography. Kidney Int; 64:2182–2187. 
Erley C. (2006) Concomitant drugs with exposure to contrast media. Kidney Int; 69  Suppl            
100:S20–S24.   
Fishbane S. (2008) N-acetylcysteine in prevention of contrast-induced nephropathy.               
Clin J Am Soc Nephrol; 3:281–287. 
Frank H, Werner D, Lorusso V, et al. (2003) Simultaneous hemodialysis during coronary             
angiography fails to prevent radiocontrast-induced nephropathy in chronic renal             
failure. Clin Nephrol; 60:176–182. 
www.intechopen.com
 
Advances in the Diagnosis of Coronary Atherosclerosis 
 
142 
From AM, Bartholmai BJ, Williams AW, etal. (2008) Sodium bicarbonate is associated with             
an increased incidence of contrast nephropathy: a retrospective cohort study of 
7977 patients at mayo clinic. Clin J Am Soc Nephrol;3:10–18. 
Gabutti L, Marone C, Monti M, etal. (2003) Does continuous veno-venous hemodiafiltration              
concomitant with radiological procedures provide a significant and safe removal of              
the iodinated contrast ioversol? Blood Purif; 21: 152–157. 
Goldenberg I, Chonchol M, Guetta V.(2009)Reversible acute kidney injury followin contrast 
exposure and the risk of long-term mortality. Am J Nephrol; 29:136–144. 
Gruberg L, Mintz GGS, Mehran R, et al. (2000)The prognostic implications of further renal             
function deterioration within 48 h of interventional coronary Procedur  in patients              
with preexistent chronic renal insufficiency. J Am Coll Cardiol; 36: 1542-1548. 
Gruberg L,Mehran R,Dangas G, etal.( 2001) Acute renal failure requiring dialysis after            
percutaneous coronary interventions. Catheter Cardiovasc Interv; 52:409- 416. 
Gupta RK, Kapoor A, Tewari S, et al. (1996) Captopril for prevention of contrast induced             
nephropathy in diabetic patients: a randomised study. Indian Heart J 1999; 51:521–
526. 
Haller C, Hizoh I. (2004)The cytotoxicity of iodinated radiocontrast agents on renal cells in 
vitro. Invest Radiol;39:149–154. 
Hamani A, Petitclerc T, Jacobs C, Deray G. (1998) Is dialysis indicated immediately after 
administration of iodinated contrast agents in patients on haemodialysis? Nephrol 
Dial Transplant  ;13:1051–1052. 
Heinrich MC, Haberle L, Muller V, et al.( 2009) Nephrotoxicity of iso-osmolar Iodixanol            
compared with nonionic low-osmolar contrast media: meta-analysis of randomized            
controlled trials. Radiology; 250:68–86. 
Heyman SN, Rosen S, Brezis M. (1994) Radiocontrast nephropathy: a paradigm for the           
synergism between toxic and hypoxic insults in the kidney. Exp Nephrol; 2:153–157. 
Heyman SN, Rosen S, Rosenberger C. (2008) Renal parenchymal hypoxia, hypoxi 
adaptation, and the pathogenesis of radiocontrast nephropathy. Clin J Am Soc 
Nephrol;3:288–296. 
Hierholzer K, Hierholzer J: The discovery of renal contrast media in berlin. Am J             
Nephrol 2002;22:295-299. 
Hirsch R, Dent C, Pfriem H, etal.( 2007) NGAL is an early predictive biomarker of  contrast-             
induced nephropathy in children. Pediatr Nephrol;22:2089–2095. 
Hoffmann U, Fischereder M, Kruger B, etal. (2004) The value of N-acetylcysteine in  the               
prevention of radiocontrast agent-induced nephropathy seems  questionable. J Am              
Soc Nephrol;15:407–410. 
Hogan SE, L’Allier P, Chetcuti S, etal. (2008) Current role of sodium bicarbonate- based                
preprocedural hydration for the prevention of contrast-induced acute  kidney               
injury: Am eta-analysis. Am Heart J; 156:414–421. 
Hricak H, Barbariv Z L(1984).Newer imaging techniques:Workshop; in Robinson I (ed): Proc             
9th Int  Cong Nephrol, , 1430-1436. 
Huber W, Eckel F, Hennig M,etal. (2006) Prophylaxis of contrast material-induced   
nephropathy in patients in intensive care: acetylcysteine, theophylline, or both? A              
randomized study. Radiology  ;239:793–804. 
Humes HD, Hunt DA, White MD. (1987) Direct toxic effect of the radiocontrast agent 
diatrizoate on renal proximal tubule cells. Am J Physiol; 252: F246–255.Isenbarger 
www.intechopen.com
 
Risks and Complication of Coronary Angiography: Contrast Related Complications 
 
143 
DW, Kent SM, O’Malley PG. (2003) Meta-analysis of randomized clinical trials on              
the usefulness of acetylcysteine for prevention of contrast  nephropathy. Am J               
Cardiol; 92:1454–1458. 
Itoh Y, Yano T, Sendo T, etal. (2006) Involvement of de novo ceramide synthesis in 
radiocontrast-induced renal tubular cell injury. Kidney Int; 69:288–297. 
James MT, Ghali WA, Tonelli M, et al. (2010) Acute kidney injury  following coronary  
angiography associated with a long-term decline in kidney function. Kidney Int;           
78:803-809. 
Kadivar Kh, McClennan BL. (2010) Intravenous Iodinated Contrast Media Reactions: 
Recognition and Response. Contemporary Diag Radiol ; 33:1-6. 
Kanter M Z. (2006) Comparison of oral and i.v acetylcysteine in the treatment of 
acetaminophen poisoning. Am J Health Syst Pharm; 63:1821–1827. 
Kay J, Chow WH, Chan TM, etal. (2003) Acetylcysteine for prevention of acute  deterioration 
of renal function following elective coronary angiography and intervention: a 
randomized controlled trial. JAMA; 289:553–558. 
Kessel DO, Robertson I, Patel J etal. (2002) Carbon-dioxide-guided vascular interventions: 
technique and pitfalls.Cardiovasc Intervent Radiol.;25(6):476. 
Klarenbach SW, Pannu N, Tonelli MA, Manns BJ. (2006) Cost-effectiveness of hemofiltration             
to prevent contrast nephropathy in patients with chronic kidney disease. Crit Care             
Med;34:1044–1051. 
Kshirsagar AV, Poole C, Mottl A, et al. (2004) N-acetylcysteine for the prevention of 
radiocontrast induced nephropathy: a meta-analysis of prospective controlled 
trials. J Am Soc Nephrol; 15:761–769. 
Kushner FG, Hand M, Smith SC Jr, et al. (2009) focused updates: ACC/AHA guidelines for            
the management of patients with ST-elevation myocardial infarction (updating the           
2004 guideline and 2007 focused update) and ACC/AHA/SCAI guidelines on            
percutaneous coronary intervention (updating the 2005 guideline and 2007 focused            
update). A report of the American College  of Cardiology Foundation/American            
Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol; 54:2205–
2241. 
Laskey WK, Jenkins C, Selzer F, et al. (2007)Volume-to-creatinine clearance ratio. J Am Coll             
Cardiol; 50:584–590. 
Lee PT, Chou KJ, Liu CP, etal. (2007) Renal protection for coronary angiography in 
advanced renal failure patients by prophylactic hemodialysis. A randomized 
controlled trial. J Am Coll Cardiol;50:1015–1020. 
Liss P, Nygren A, Erikson U, Ulfendahl HR. (1998) Injection of low and iso-osmolar  contrast              
medium decreases oxygen tension in the renal medulla. Kidney  Int;53:698–702. 
Liss P, Carlsson PO, Palm F, Hansell P. (2004) Adenosine A1 receptors in contrast  media-             
induced renal dysfunction in the normal rat. Eur Radiol;14:1297–1302. 
Liss P, Eklöf H, Hellberg O, etal. (2005) Renal effects of CO2 and iodinated contrast media in            
patients undergoing renovascular intervention: a prospective, randomized study. J            
Vasc Interv Radiol.;16(1):57. 
Liss P, Persson PB, Hansell P, Lagerqvist B. (2006) Renal failure in 57 925 patients 
undergoing coronary procedures using isosmolar or low-osmolar contrast media.             
Kidney Int  ;70:1811–1817. 
www.intechopen.com
 
Advances in the Diagnosis of Coronary Atherosclerosis 
 
144 
Liu R, Nair D, Ix J, et al. (2005) N-acetylcysteine for the prevention of contrast- induced             
nephropathy: a systematic review and meta-analysis. J Gen Intern Med;20:193–200. 
Manske CL, Sprafka JM, Strony JT, Wang Y. (1990) Contrast nephropathy in azotemic 
diabetic patients undergoing coronary angiography. Am J Med; 89:615–620. 
Maioli M, Toso A, Leoncini M, etal. (2008) Sodium bicarbonate versus Saline for the 
prevention of contrast-induced nephropathy in Patients with renal dysfunction             
undergoing coronary angiography or intervention. J Am Coll Cardiol;52:599–604. 
Marenzi G, Marana I, Lauri G, et al. (2003) The prevention of  radio contrast- agent induced               
nephropathy by hemofiltration. N Engl J Med; 349:1333–1340.   
Marenzi G, Lauri G, Assanelli E, et al. (2004) Contrast-induced nephropathy in patients              
undergoing primary angioplasty for acute myocardial infarction. J  Am Coll  Cardiol;              
44:1780–1785. 
Marenzi G, Lauri G, Campodonico J, et al. (2006b) Comparison of two hemofiltration 
protocols for prevention of contrast-induced nephropathy in   high –risk patients.               
Am J Med; 119:155-162 
Marenzi G, Assanelli E, Marana I, etal. (2006a) N-acetylcysteine and contrast-induced 
nephropathy in primary angioplasty. N Engl J Med;354:2773–2782. 
Marenzi G, Assanelli E, Campodonico J, etal. (2009) Contrast volume during primary 
percutaneous coronary intervention and subsequent contrast-induced nephropathy 
and mortality. Ann Intern Med; 150:170–177. 
Masuda M, Yamada T, Mine T, et al. (2007) Comparison of usefulness of sodium bicarbonate 
versus sodium chloride to prevent contrast-induce  nephropathy in patients 
undergoing emergent coronary procedure. Am J  Cardiol; 100:781–786. 
McCullough PA, Wolyn R, Rocher LL, et al. (1997) Acute renal failure after coronary 
intervention: incidence, risk factors, and relationship to mortality. Am J Med; 
103:368–375. 
McCullough P A, Soman S S. (2005) Contrast-induced nephropathy. Crit Care Clin; 21:261–               
280. 
McCullough PA, Adam A, Becker CR, etal. (2006a) Epidemiology and prognostic 
implications of contrast-induced nephropathy. Am J Cardiol;98:5K–13K. 
McCullough PA, Adam A, Becker CR, et al. (2006b) Risk prediction of contras induced               
nephropathy. Am J Cardiol; 98:27K–36K. 
McCullough PA, Bertrand ME, Brinker JA, Stacul F. (2006c) A meta-analysis of the renal             
safety of isosmolar iodixanol compared with low-osmolar contrast media. J Am Coll             
Cardiol; 48:692–699. 
Mehran R, Aymong ED, Nikolsky E, et al. (2004) A simple risk score for prediction of  
contrast-induced nephropathy after percutaneous coronary intervention:  
development and initial validation. J Am Coll Cardiol; 44:1393–1399. 
Merten GJ, Burgess WP, Gray LV, et al. (2004) Prevention of contrast-induced nephropathy              
with sodium bicarbonate: a randomized controlled trial. JAMA; 291:2328–2334. 
Mockel M, Radovic M, Kuhnle Y, etal. (2008) Acute renal haemodynamic effects of 
radiocontrast media in patients undergoing left ventricular and coronary 
angiography. Nephrol Dial Transplant;23:1588–1594 
Morcos S K, Thomsen H S, Webb J A W and members of contrast media safety committee of               
the European Society of Urogenital Radiology (ESUR). (1999) Contrast media              
induced nephropathy: a consensus report. Eur Radiol;9:1602-1613. 
www.intechopen.com
 
Risks and Complication of Coronary Angiography: Contrast Related Complications 
 
145 
Morcos SK, Thomsen HS, Webb JA. (2002) Dialysis and contrast media. Eur Radiol; 12: 3026–
3030. 
Morcos SK. (2005) Prevention of contrast media-induced nephrotoxicity after angiographic              
procedures. J Vasc Interv Radiol;16:13–23. 
Mueller C, Buerkle G, Buettner HJ, et al. (2002) Prevention of contrast media associated               
nephropathy: randomized comparison of 2 hydration regimens in 1620 patients              
undergoing coronary angioplasty. Arch Intern Med; 162:329–336. 
Nallamothu BK, Shojania KG, Saint S, et al. (2004) Is acetylcysteine effective in preventing              
contrast-related nephropathy? A meta-analysis. Am J Med; 117:938–947. 
Nash K, Hafeez A, Hou S. (2002) Hospital-acquired renal insufficiency. Am J Kidney  Dis;               
39:930–936. 
Nikolsky E, Mehran R, Lasic Z, etal. (2005) Low hematocrit predicts contrast-induced 
nephropathy after percutaneous coronary interventions. Kidney Int;67:706–713. 
Onbasili AO, Yenicerioglu Y, Agaoglu P, et al. (2007) Trimetazidine in the prevention of             
contrast-induced nephropathy after coronary procedures. Heart;93:654-655. 
Ozcan EA, Guneri S, Akdeniz B, et al. (2007) Sodium bicarbonate, N acetylcysteine, and              
saline for prevention of radio-contrast-induced nephropathy. A  comparison of 3             
regimens for protecting contrast-induced nephropathy in patients undergoing             
coronary procedures. A single-center prospective  controlled trial. Am Heart J;             
154:539–544. 
Pannu N, Manns B, Lee H, Tonelli M. (2004) Systematic review of the impact of N- 
acetylcysteine on contrast nephropathy. Kidney Int; 65:1366–1374 
Peer A, Averbukh Z, Berman S, etal.(2003) Contrast media augmented apoptosis of cultured             
renal mesangial, tubular, epithelial, endothelial, and hepatic cells. Invest Radiol;              
38:177–182 
PerazellaMA.(2009)Radiocontrast-induced nephropathy: an update. Minerva Urol Nefrol ;             
61:215-233. 
Persson PB (2005).Contrast medium-induced nephropathy. Nephrol Dial Transplant; 20 Suppl               
1:i1 
Persson PB, Tepel M.(2006) Contrast medium-induced nephropathy: the pathophysiology.            
Kidney Int Suppl; 100:S8–10. 
Pflueger A, Larson TS, Nath KA, et al. (2000) Role of adenosine in contrast media  induced             
acute renal failure in diabetes mellitus. Mayo Clin Proc; 75:1275–1283. 
Ranucci M, Ballotta A, Kunkl A, et al.( 2008)Influence of the timing of cardiac catheterization 
and the amount of contrast media on acute renal failure after cardiac  surgery. Am J 
Cardiol; 101:1112–1118. 
Recio-Mayoral A, Chaparro M, Prado B, et al. (2007) The reno-protective effect of hydration            
with sodium bicarbonate plus N-acetylcysteine in patients  undergoing emergency               
percutaneous coronary intervention: the RENO  study. J Am Coll Cardiol; 49:1283–            
1288. 
Reed M, Meier P, Tamhane U U, etal.( 2009)The relative safety of Iodixanol compared with             
low-osmolar contrast media: a meta-analysis of randomized controlled  trials. J Am             
Coll Cardiol;2:645-654. 
Ribeiro L, de Assuncao e Silva F, Kurihara RS, etal. (2004) Evaluation of the nitric  oxide             
production in rat renal artery smooth muscle cells culture exposed to  radiocontrast            
agents. Kidney Int; 65: 589–96. 
www.intechopen.com
 
Advances in the Diagnosis of Coronary Atherosclerosis 
 
146 
Ribichini F, Graziani M, Gambaro G, etal. (2010) Early Creatinine shifts Predict Contrast-            
induced Nephropathy and persistent renal damage after angiography. Am J Med;             
123:755-763. 
Rihal CS, Textor SC, Grill DE, et al. (2002) Incidence and prognostic importance of acute            
renal failure after percutaneous coronary intervention. Circulation; 105:2259–2264. 
Rudnick M R,Goldfarb S,Wexler L,etal. (1995)Nephrotoxicity of ionic and   nonionic contrast 
media in 1196 patients: A randomized trial: the Iohexol Cooperative Study.            
KidneyInt;47:254-261. 
Rudnick M, Kesselheim A, Goldfarb S. (2006) Contrast-induced nephropathy: how it 
develops, how to prevent it. Cleveland Clin J Med; 73:75–87. 
Rudnick M, Goldfarb S. (2003) Pathogenesis of contrast-induced nephropathy: Experimental             
and clinical observations with an emphasis on the role of osmolality. Rev Cardiovasc  
ed; 4 (Suppl 5):S28–S33. 
Rudnick MR, Davidson C, Laskey W, et al.( 2008) Nephrotoxicity of iodixanol versus              
ioversol in patients with chronic renal disease. The visipaque angiography 
/interventions with laboratory outcomes in renal insufficiency (VALOR) trial.            
Am Heart J;156:776-782. 
Rudnick M, Feldman H. (2008) Contrast-induced nephropathy: what are the true clinical             
consequences? Clin J Am Soc Nephrol; 3:263–272. 
Sayol A J, Bush W H. (2011) Avoidable errors in dealing with anaphylactoid reactions to             
iodinated contrast media. Invest Radiol;46: 147–151. 
Seeliger E, Flemming B, Wronski T, et al.( 2007) Viscosity of contrast media perturbs renal            
hemodynamics. J Am Soc Nephrol; 18:2912–2920. 
Shah SH, Mehta RL. Acute kidney injury in critical care:time for a paradigm shift? Curr Opin            
Nephrol Hypertens  2006;15:561– 565. 
Shaw DR, Kessel DO. (2006) The current status of the use of carbon dioxide in  diagnostic            
and interventional angiographic procedures. Cardiovasc Intervent  Radiol. ;29(3):323. 
Solomon R, Werner C, Mann D, et al. (1994) Effects of saline, mannitol, and furosemide to             
prevent acute decreases in renal function induced by  radiocontrast agents. N Engl J             
Med; 331:1416–1420. 
Solomon R. (2005)The role of osmolality in the incidence of contrast induced nephropathy:              
A systematic review of angiographic contrast media in high risk patients.  Kidney             
Int;68:2256–2263. 
Solomon R, Dumouchel W. ( 2006) Contrast media and nephropathy: findings from 
systematic analysis and Food and Drug Administration reports of adverse  effects.             
Invest Radiol; 41:651-660. 
Solomon R , Natarajan MK, Doucet S, et al. (2007) Cardiac angiography in renally  impaired            
patients (CARE) study: A randomized double-blind trial of contrast induced             
nephropathy in patients with chronic kidney disease.  Circulation; 115:3189–3196. 
Solomon RJ, Mehran R, Natarajan MK, et al. (2009) Contrast-induced nephropathy  and            
long-term adverse events: cause and effect? Clin J Am Soc Nephrol; 4:1162–1169. 
Spargias K, Alexopoulos E, Kyrzopoulos S, et al. (2004) Ascorbic acid prevents  contrast-            
mediated nephropathy in patients with renal dysfunction  undergoing coronary             
angiography or intervention. Circulation; 110:2837–2842. 
Stevens MA, McCullough PA, Tobin KJ, et al. (1999) A prospective randomized trial of            
prevention measures in patients at high risk for contrast nephropathy: results of the           
www.intechopen.com
 
Risks and Complication of Coronary Angiography: Contrast Related Complications 
 
147 
P.R.I.N.C.E. study. Prevention of radiocontrast induced  nephropathy clinical            
evaluation. J Am Coll Cardiol; 33:403–411. 
Subramanian S, Tumlin J, Bapat B, Zyczynski T. (2007) Economic burden of contrast- 
induced nephropathy: implications for prevention strategies. J Med Econ; 10:119–
134. 
Taylor AJ, Hotchkiss D, Morse RW, McCabe J. (1998) PREPARED: Preparation for 
angiography in Renal Dysfunction: a randomized trial of inpatient vs. outpatient             
hydration protocols for cardiac catheterization in mild-to-moderate renal            
dysfunction. Chest; 114:1570–1574.  
Tepel M, van der Giet M, Schwarzfeld C, et al. (2000) Prevention of radiographic  contrast-             
agent-induced reductions in renal function by acetylcysteine. N  EnglJ Med; 
343:180–184. 
Tepel M, Aspelin P, Lameire N. (2006) Contrast-induced nephropathy: a clinical and 
evidence-based approach. Circulation;113:1799–806. 
The Committee on Drugs and Contrast Media of the American College of Radiology  (2010). 
Contrast nephropathy. In: ACR manual oncontrast media,Version 7.28  American 
College of Radiology, Retrieved from: http://www.acr.org/ 
secondarymainmenucategories/quality_safety/contrast_manual/fullmanual.aspx  
Thomsen H S. (2005)How to avoid CIN: guidelines from the European Society of  Urogenital 
Radiology. Nephrol Dial Transplant; 20 (Suppl 1):i18– i22. 
Thomsen H S, Morcos S K, Members of Contrast Media Safety Committee of European                 
Society of Urogenital Radiology (ESUR). (2005) In which patients  should serum                 
creatinine be measured before contrast medium  administration? Eur Radiol, 15:                  
749–756. 
Thomsen H S, Morcos SK. (2006) ESUR guidelines on contrast media. Abdom Imaging; 31:                
131–140. 
Thomsen HS. (2006) Reducing the risk of contrast media induced nephrotoxicity. In:                  
Contrast media: safety issues and ESUR Guidelines. Thomsen HS (ed) 53–55                  
Springer, 978-3-540-72783-5  Heidelberg Berlin New York,; pp. 
Thomsen HS, Morcos SK, Erley CM, et al. (2008)The ACTIVE trial: comparison of the  effects                   
on renal function of iomeprol-400 and iodixanol-320 in patients with  chronic                   
kidney disease undergoing abdominal computed tomography. Invest Radiol;                 
43:170–178. 
Toprak O, Cirit M, Bayata S, etal. (2003) The effect of preprocedural captopril on   contrast-                  
induced nephropathy in patients who underwent coronary  angiography.                   
(abstract)  Anadolu Kardiyol Derg;3:98-103. 
Toprak O, Cirit M.(2006) Risk factors and therapy strategies for contrast-
inducednephropathy. Renal Fail;28:365–381. 
Trivedi HS, Moore H, Nasr S, et al. (2003) A randomized prospective trial to assess the role                 
of saline hydration on the development of contrast nephrotoxicity. Nephron Clin                
Pract; 93:c29–c34. 
Ultramari FT, Bueno Rda R, da Cunha CL, et al.(2006)Contrast media-induced  nephropathy                 
following diagnostic and therapeutic cardiac catheterization.  Arq bras Cardiol;                  
87:378–90. 
Vasheghani -Farahani A, Sadigh G, Kassaian S E etal. (2009)Sodium Bicarbonate Plus 
Isotonic Saline Versus Saline for Prevention of contrast-induced  nephropathy in                 
www.intechopen.com
 
Advances in the Diagnosis of Coronary Atherosclerosis 
 
148 
patients undergoing coronary angiography: A  randomized controlled trial; Am J                
Kidney Dis 54:610-618. 
Vasheghani-Farahani A ,Sadigh G ,Kassaian S, etal. (2010) Sodium bicarbonate in  
preventing contrast nephropathy in patients at risk for volume overload: a 
randomized controlled trial. J Nephrol; 23:216–223. 
Vogt B, Ferrari P, Schonholzer C, et al. (2001) Prophylactic hemodialysis after radiocontrast                
media in patients with renal insufficiency is potentially  harmful. Am J Med; 111:                
692–698. 
Weinmann H J, Platzec J, Schirmer H etal.(2005) Contrast media: future aspects. Eur Radiol15              
(Suppl4):D70-D73 
Weisberg LS, Kurnik PB, Kurnik BR (1992) Radiocontrastinduced nephropathy in  humans:              
role of renal vasoconstriction. Kidney Int 41:1408–1415. 
Weisberg LS, Kurnik PB, Kurnik BR. (1994) Risk of radiocontrast nephropathy in patients             
with and without diabetes mellitus. Kidney Int;45:259–265. 
Weisbord SD, Chen H, Stone RA, etal.(2006)Associations of increases in serum  Creatinine              
with mortality and length of hospital stay after coronary  angiography.  J Am Soc             
Nephrol ; 17:2871–2877. 
Weisbord SD, Pavelsky PM. (2008) Prevention of contrast-induced nephropathy with 
volume expansion. Clin J Am Soc Nephrol; 3:273–280. 
Yokomaku Y, Sugimoto T, Kume S, et al. (2008) Asialoerythropoietin prevents  contrast-               
induced nephropathy. J Am Soc Nephrol; 19:321–328. 
Zagler A, Azadpour M, Mercado C, Hennekens CH. (2006) N-acetylcysteine and contrast-
induced nephropathy: a meta-analysis of 13 randomized trials.  Am Heart J; 
151:140–145. 
www.intechopen.com
Advances in the Diagnosis of Coronary Atherosclerosis
Edited by Prof. Suna Kirac
ISBN 978-953-307-286-9
Hard cover, 378 pages
Publisher InTech
Published online 09, November, 2011
Published in print edition November, 2011
InTech Europe
University Campus STeP Ri 
Slavka Krautzeka 83/A 
51000 Rijeka, Croatia 
Phone: +385 (51) 770 447 
Fax: +385 (51) 686 166
www.intechopen.com
InTech China
Unit 405, Office Block, Hotel Equatorial Shanghai 
No.65, Yan An Road (West), Shanghai, 200040, China 
Phone: +86-21-62489820 
Fax: +86-21-62489821
Coronary artery disease (CAD) and its consequences are most important morbidity and mortality reasons in
the developed and developing countries. To prevent hard end-points, early definitive diagnosis and optimum
therapy play significant role. Novel advanced diagnostic tests which are biomarkers of inflammation, cell
adhesion, cell activation and imaging techniques provide to get the best result in the detection and
characterization of calcified or uncalcified atherosclerotic plaques. In spite of last developments in the imaging
methods, coronary catheterization is still frequently performed. Following the first cardiac catheterization
performed in 1844, date by date historical developments and the mechanics of cardiac catheterization
techniques, risks associated with coronary angiography, and also, preventions and treatments of possible
complications have been presented in this book. Other important issue is radiation exposure of patients and
staff during coronary angiography and scintigraphy. Radiation dose reduction techniques, general radiation
protection principles have been discussed in related chapters.
How to reference
In order to correctly reference this scholarly work, feel free to copy and paste the following:
S. Mohammad Reza Khatami (2011). Risks and Complications of Coronary Angiography: Contrast Related
Complications, Advances in the Diagnosis of Coronary Atherosclerosis, Prof. Suna Kirac (Ed.), ISBN: 978-953-
307-286-9, InTech, Available from: http://www.intechopen.com/books/advances-in-the-diagnosis-of-coronary-
atherosclerosis/risks-and-complications-of-coronary-angiography-contrast-related-complications
© 2011 The Author(s). Licensee IntechOpen. This is an open access article
distributed under the terms of the Creative Commons Attribution 3.0
License, which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
